JP2019526628A - セニクリビロクメシレートの固体形態及びセニクリビロクメシレートの固体形態を製造するプロセス - Google Patents

セニクリビロクメシレートの固体形態及びセニクリビロクメシレートの固体形態を製造するプロセス Download PDF

Info

Publication number
JP2019526628A
JP2019526628A JP2019531594A JP2019531594A JP2019526628A JP 2019526628 A JP2019526628 A JP 2019526628A JP 2019531594 A JP2019531594 A JP 2019531594A JP 2019531594 A JP2019531594 A JP 2019531594A JP 2019526628 A JP2019526628 A JP 2019526628A
Authority
JP
Japan
Prior art keywords
crystalline form
compound
msoh
acetonitrile
ethyl acetate
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2019531594A
Other languages
English (en)
Japanese (ja)
Other versions
JP2019526628A5 (enExample
Inventor
パシット・フィアシヴォンサ
マーティン・イアン・クーパー
エマ・ケイ・シャープ
Original Assignee
トビラ セラピューティクス， インコーポレイテッド
トビラ セラピューティクス， インコーポレイテッド
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by トビラ セラピューティクス， インコーポレイテッド, トビラ セラピューティクス， インコーポレイテッド filed Critical トビラ セラピューティクス， インコーポレイテッド
Publication of JP2019526628A publication Critical patent/JP2019526628A/ja
Publication of JP2019526628A5 publication Critical patent/JP2019526628A5/ja
Priority to JP2022113230A priority Critical patent/JP2022137223A/ja
Pending legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C309/00—Sulfonic acids; Halides, esters, or anhydrides thereof
    • C07C309/01—Sulfonic acids
    • C07C309/02—Sulfonic acids having sulfo groups bound to acyclic carbon atoms
    • C07C309/03—Sulfonic acids having sulfo groups bound to acyclic carbon atoms of an acyclic saturated carbon skeleton
    • C07C309/04—Sulfonic acids having sulfo groups bound to acyclic carbon atoms of an acyclic saturated carbon skeleton containing only one sulfo group
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
    • C07B2200/00—Indexing scheme relating to specific properties of organic compounds
    • C07B2200/13—Crystalline forms, e.g. polymorphs

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • General Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Epidemiology (AREA)
  • Urology & Nephrology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
JP2019531594A 2016-08-31 2017-08-30 セニクリビロクメシレートの固体形態及びセニクリビロクメシレートの固体形態を製造するプロセス Pending JP2019526628A (ja)

Priority Applications (1)

Application Number Priority Date Filing Date Title
JP2022113230A JP2022137223A (ja) 2016-08-31 2022-07-14 セニクリビロクメシレートの固体形態及びセニクリビロクメシレートの固体形態を製造するプロセス

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201662382153P 2016-08-31 2016-08-31
US62/382,153 2016-08-31
PCT/US2017/049400 WO2018045043A1 (en) 2016-08-31 2017-08-30 Solid forms of cenicriviroc mesylate and processes of making solid forms of cenicriviroc mesylate

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2022113230A Division JP2022137223A (ja) 2016-08-31 2022-07-14 セニクリビロクメシレートの固体形態及びセニクリビロクメシレートの固体形態を製造するプロセス

Publications (2)

Publication Number Publication Date
JP2019526628A true JP2019526628A (ja) 2019-09-19
JP2019526628A5 JP2019526628A5 (enExample) 2020-10-08

Family

ID=61241572

Family Applications (2)

Application Number Title Priority Date Filing Date
JP2019531594A Pending JP2019526628A (ja) 2016-08-31 2017-08-30 セニクリビロクメシレートの固体形態及びセニクリビロクメシレートの固体形態を製造するプロセス
JP2022113230A Pending JP2022137223A (ja) 2016-08-31 2022-07-14 セニクリビロクメシレートの固体形態及びセニクリビロクメシレートの固体形態を製造するプロセス

Family Applications After (1)

Application Number Title Priority Date Filing Date
JP2022113230A Pending JP2022137223A (ja) 2016-08-31 2022-07-14 セニクリビロクメシレートの固体形態及びセニクリビロクメシレートの固体形態を製造するプロセス

Country Status (13)

Country Link
US (1) US10301287B2 (enExample)
EP (1) EP3506896A4 (enExample)
JP (2) JP2019526628A (enExample)
KR (1) KR20190057066A (enExample)
CN (1) CN110167550A (enExample)
AU (1) AU2017321594A1 (enExample)
BR (1) BR112019003987A2 (enExample)
CA (1) CA3034606A1 (enExample)
MX (1) MX2019002057A (enExample)
RU (1) RU2019109019A (enExample)
SG (1) SG11201901438VA (enExample)
TW (1) TW201823235A (enExample)
WO (1) WO2018045043A1 (enExample)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPWO2022177014A1 (enExample) * 2021-02-22 2022-08-25

Families Citing this family (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2019238041A1 (zh) * 2018-06-12 2019-12-19 南京明德新药研发有限公司 一种丙烯酰胺类化合物的晶型及其制备方法
WO2019245518A1 (en) * 2018-06-18 2019-12-26 Hewlett-Packard Development Company, L.P. Three-dimensional printing
WO2019245517A1 (en) * 2018-06-18 2019-12-26 Hewlett-Packard Development Company, L.P. Three-dimensional printing
US11426931B2 (en) 2018-06-19 2022-08-30 Hewlett-Packard Development Company, L.P. Three-dimensional printing
WO2019245535A1 (en) 2018-06-19 2019-12-26 Hewlett-Packard Development Company, L.P. Three-dimensional printing
US11298876B2 (en) 2018-06-19 2022-04-12 Hewlett-Packard Development Company, L.P. Three-dimensional printing
EP3844209B1 (en) * 2018-08-31 2022-06-22 Evonik Operations GmbH Process for preparing a polymer powder
WO2021133811A1 (en) 2019-12-26 2021-07-01 Teva Pharmaceuticals International Gmbh Solid state forms of cenicriviroc and process for preparation thereof
WO2021233349A1 (zh) 2020-05-22 2021-11-25 南京明德新药研发有限公司 吡啶类衍生物及其应用

Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2004123694A (ja) * 2002-03-12 2004-04-22 Takeda Chem Ind Ltd 光学活性スルホキシド誘導体の製造法
JP2007269628A (ja) * 2004-05-28 2007-10-18 Takeda Chem Ind Ltd 医薬化合物の結晶
JP2013136629A (ja) * 2001-08-08 2013-07-11 Tobira Therapeutics Inc 二環性化合物、その製造法および用途
WO2016105527A1 (en) * 2014-12-23 2016-06-30 Tobira Therapeutics, Inc. Process of making cenicriviroc and related analogs

Family Cites Families (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS62265270A (ja) 1986-05-13 1987-11-18 Zeria Shinyaku Kogyo Kk 新規イミダゾ−ル誘導体およびそれらを有効成分とする抗潰瘍剤
DE69520360T2 (de) 1994-07-04 2001-08-09 Takeda Chemical Industries, Ltd. Phosphonsäure verbindungen imre herstellung und verwendung
CN1282243A (zh) 1997-12-19 2001-01-31 武田药品工业株式会社 用于拮抗ccr5的含n－酰苯胺衍生物的药物组合物
AU5301599A (en) 1998-08-20 2000-03-14 Takeda Chemical Industries Ltd. Quaternary ammonium salts and their use
WO2001017947A1 (en) 1999-09-06 2001-03-15 Takeda Chemical Industries, Ltd. Process for the preparation of 2,3-dihydroazepine compounds
US20080249147A1 (en) 2004-03-24 2008-10-09 Takeda Pharmaceutical Company Limited Emulsion-Stabilized Preparation
GT200600148A (es) 2005-04-14 2006-11-22 Metodos para el tratamiento y la prevencion de fibrosis
PE20140406A1 (es) 2010-11-18 2014-04-16 Univ Yale Moleculas bifuncionales con actividad de reclutamiento de anticuerpos y actividad inhibitoria inicial contra el virus de la inmunodeficiencia humana
EP2846788A1 (en) * 2012-05-11 2015-03-18 Akron Molecules AG Use of compounds for the treatment of pain
UA115807C2 (uk) 2013-05-15 2017-12-26 Тобіра Терап'Ютикс, Інк. Композиція (варіанти) ценікривіроку і спосіб її одержання та застосування (варіанти)
RU2020119611A (ru) 2014-03-21 2020-06-29 Тобира Терапьютикс, Инк. Сенекривирок для лечения фиброза
US20170105969A1 (en) 2014-06-02 2017-04-20 Tobira Therapeutics, Inc. Cenicriviroc for the treatment of hiv-2 infection

Patent Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2013136629A (ja) * 2001-08-08 2013-07-11 Tobira Therapeutics Inc 二環性化合物、その製造法および用途
JP2004123694A (ja) * 2002-03-12 2004-04-22 Takeda Chem Ind Ltd 光学活性スルホキシド誘導体の製造法
JP2007269628A (ja) * 2004-05-28 2007-10-18 Takeda Chem Ind Ltd 医薬化合物の結晶
WO2016105527A1 (en) * 2014-12-23 2016-06-30 Tobira Therapeutics, Inc. Process of making cenicriviroc and related analogs

Non-Patent Citations (4)

* Cited by examiner, † Cited by third party
Title
J.MED.CHEM., vol. 49, JPN6021024529, 2006, pages 2037 - 2048, ISSN: 0004727164 *
生活工学研究, vol. 4, JPN6014015069, 2002, pages 310 - 317, ISSN: 0004727166 *
社団法人日本化学会, 実験化学ガイドブック, JPN6008055044, 1992, pages 130 - 131, ISSN: 0004727165 *
高田則幸: "創薬段階における原薬Formスクリーニングと選択", PHARM STAGE, vol. 6, no. 10, JPN6009053755, 15 January 2007 (2007-01-15), pages 20 - 25, ISSN: 0004727167 *

Cited By (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPWO2022177014A1 (enExample) * 2021-02-22 2022-08-25
JP7374372B2 (ja) 2021-02-22 2023-11-06 旭化成株式会社 セルロースナノファイバーを含む組成物

Also Published As

Publication number Publication date
BR112019003987A2 (pt) 2019-05-28
MX2019002057A (es) 2019-11-18
US20180057481A1 (en) 2018-03-01
CN110167550A (zh) 2019-08-23
RU2019109019A (ru) 2020-10-01
AU2017321594A1 (en) 2019-04-18
RU2019109019A3 (enExample) 2021-08-23
TW201823235A (zh) 2018-07-01
JP2022137223A (ja) 2022-09-21
EP3506896A4 (en) 2020-08-26
SG11201901438VA (en) 2019-03-28
WO2018045043A1 (en) 2018-03-08
US10301287B2 (en) 2019-05-28
KR20190057066A (ko) 2019-05-27
CA3034606A1 (en) 2018-03-08
EP3506896A1 (en) 2019-07-10

Similar Documents

Publication Publication Date Title
US10301287B2 (en) Solid forms of cenicriviroc mesylate and processes of making solid forms of cenicriviroc mesylate
US12291517B2 (en) Crystalline form of 6-(cyclopropanecarboxamido)-4-((2-methoxy-3-(1-methyl-1H-1,2,4-triazol-3-yl)phenyl)amino)-n-(methyl-D3) pyridazine-3-carboxamide
JP7086118B2 (ja) Ｌ－オルニチンフェニルアセテートおよびその製造方法
JP6081763B2 (ja) ダサチニブ多形体およびその調製プロセス
US10188648B2 (en) Solid state forms of selexipag
US12209073B2 (en) Polymorphs of a dihydroorotate dehydrogenase (DHOD) inhibitor
JP2013540810A (ja) １−｛（２Ｓ）−２−アミノ−４−［２，４−ビス（トリフルオロメチル）−５，８−ジヒドロピリド［３，４−ｄ］ピリミジン−７（６Ｈ）−イル］−４−オキソブチル｝−５，５−ジフルオロピペリジン−２−オン酒石酸塩の水和物
WO2018022704A1 (en) Crystalline form vi of selexipag
JP2005298424A (ja) エパルレスタット結晶の製造方法
WO2025011259A1 (zh) 瑞司美替罗的晶型及其制备方法和用途
US20210284611A1 (en) Highly stable crystalline eltrombopag monoethanolamine salt form d1
TW202021960A (zh) 貝前列素-314d單水合物晶體及其製備方法
US20220372024A1 (en) Crystalline forms of entrectinib
EP3484471B1 (en) Method for producing a polymorphic form of 3-[5-amino-4-(3- cyanobenzoyl)-pyrazol-1-yl]-n-cyclopropyl-4-methylbenzamide
JP2024545530A (ja) 縮合環誘導体の結晶形、その製造方法、及びその使用
WO2019086008A1 (zh) 一种苯并三氮唑衍生物的晶型及其制备方法和用途
TW200302830A (en) Anhydrate/hydrate of an erythromycin derivative and processes for preparing said anhydrate/hydrate
TW200533678A (en) A novel crystal of a triterpene derivative
HK1245770B (zh) 尿嘧啶化合物的结晶

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20200828

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20200828

A977 Report on retrieval

Free format text: JAPANESE INTERMEDIATE CODE: A971007

Effective date: 20210624

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20210629

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20210921

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20211224

A02 Decision of refusal

Free format text: JAPANESE INTERMEDIATE CODE: A02

Effective date: 20220315